PENGEMBANGAN KIT DIAGNOSTIK BERBASIS ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) SEBAGAI ALAT EVALUASI KEBERHASILAN VAKSINASI COVID-19
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) virus. The disease was first detected in 2019 and now it has spread to more than 228 countries. COVID-19 data in Indonesia shows that this disease infected more tha...
Saved in:
| Main Author: | |
|---|---|
| Format: | Final Project |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/67729 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) virus. The disease was first detected in 2019 and now it has spread to more than 228 countries. COVID-19 data in Indonesia shows that this disease infected more than 6 million people and caused more than 156,000 mortalities. There is no cure for the disease and the response to COVID-19 is through prevention, one of which is through vaccination. The Indonesian government has implemented a COVID-19 vaccination program, that has reached more than 200 million people. However, the program was not followed by an evaluation to determine the success of the vaccination. Institut Teknologi Bandung is currently developing an ELISA (Enzyme-Linked Immunosorbent Assay)-based COVID-19 diagnostic kit that can be used to detect the presence of anti spike (S1) protein antibodies semi-quantitatively. The concept of the diagnostic kit has been carried out and the design was proven capable of detecting the presence of IgG anti S1 protein. However, the diagnostic kit is still at the Technological Readiness level of 4 (TRL-4), that is still unsuitable to be used in actual test conditions (clinical laboratory). This study was conducted to further develop the diagnostic kit to Technological Readiness Level of 6 (TRL-6), so the diagnostic kit can be used at the clinical laboratory. The results of this study indicate that the uses of glycine buffer pH 2.5 and the application of 2 washing steps, each with 5 cycles using 1 minute incubation between washing cycle lead to false negative result, where positive and negative samples was completely washed away. This problem was overcome with the use of glycine buffer pH 4 as the washing solution. Furthermore, it was also found that the incubation time between washing cycle had no effect on the absorbance background. This research succeeded in further developing the COVID-19 diagnostic kit that can use blood serum, blood plasma and whole blood as samples.
|
|---|